NCT04009681 2025-12-15
HAMMER
Synthorx, Inc, a Sanofi company
Phase 1/2 Terminated
Clinical Trials
23 trialsNCT04717375 2025-08-07
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT06024174 2025-07-22
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03563157 2024-12-11
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT01884740 2022-08-09
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT02117466 2021-04-14
IMPACT-CRC
Amsterdam UMC, location VUmc
Phase 1/2 Terminated
NCT02822482 2021-03-29
COPAN-ORL06
UNICANCER
Phase 1/2 Terminated
NCT01602315 2020-12-29
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Novartis
Phase 1/2 Terminated
NCT02855086 2020-03-31
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
Stanford University
Phase 1/2 Terminated
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT01009346 2018-07-17
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT00226941 2017-12-08
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
Stanford University
Phase 1/2 Terminated
NCT00570674 2017-11-13
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00361244 2017-02-17
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT00927147 2017-01-31
Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer
Boneca Corporation
Phase 1/2 Terminated
NCT01042028 2015-10-20
A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
Odense University Hospital
Phase 1/2 Terminated
NCT00908024 2013-06-18
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT01611506 2013-01-09
Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Terminated
NCT01015664 2012-12-17
Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
University of Tennessee Cancer Institute
Phase 1/2 Terminated